Stockscreener 앱 받기
52.59
0.07%
-0.035
Soleno Therapeutics Inc 주식(SLNO)의 최신 뉴스
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
SLNO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - PR Newswire
Trading the Move, Not the Narrative: (SLNO) Edition - Stock Traders Daily
2026-04-12 | SLNO STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:SLNO | Press Release - Stockhouse
NASDAQ: SLNO: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Soleno Therapeutics, Inc. - The Globe and Mail
FinancialContentNASDAQ: SLNO: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Soleno Therapeutics, Inc. - FinancialContent
SLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - marketscreener.com
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSLNO - ACCESS Newswire
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - PR Newswire
Neurocrine Biosciences, Inc. (NBIX) Soleno Therapeutics, Inc.M&A CallSlideshow (NASDAQ:NBIX) 2026-04-10 - Seeking Alpha
SLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit Investors ... - Bluefield Daily Telegraph
SLNO Shareholder Alert: Soleno Therapeutics, Inc. - GlobeNewswire
INVESTOR NOTICE: Soleno Therapeutics (SLNO) Investors with Substantial Losses Have Opportunity to Lead Investor Class ActionHagens Berman - Sahm
TD Cowen Downgrades Soleno Therapeutics to 'Hold' - National Today
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Super Micro Computer, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
SLNO DEADLINE NOTICE: Soleno Therapeutics, Inc. Investors Encouraged to Contact Kirby McInerney LLP By May 5, 2026 - ACCESS Newswire
Rosen Law Firm Encourages Soleno Therapeutics Investors to Secure Counsel Before Deadline - National Today
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Soleno Therapeutics, Inc. Investors with ... - Caledonian Record
ROSEN, A LEADING LAW FIRM, Encourages Eos Energy Enterprises, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – EOSE - GlobeNewswire Inc.
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages - GlobeNewswire
SLNO Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - marketscreener.com
SOLENO LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces - GlobeNewswire
Soleno Therapeutics Investors Seek Lead in Class Action Lawsuit - National Today
INVESTOR NOTICE: Soleno Therapeutics (SLNO) Investors with Subst - GuruFocus
Bronstein, Gewirtz & Grossman LLC Urges Soleno - GlobeNewswire
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSLNO - PR Newswire
SOLENO THERAPEUTICS, INC. (SLNO) DEADLINE ALERT Bernstein - GlobeNewswire
Soleno Therapeutics (SLNO) still appears attractive despite slower US launch ramp projections - MSN
Soleno Therapeutics Downgraded to 'Hold' by Cantor Fitzgerald - National Today
United StatesGoodwin Advises Centerview And Guggenheim On $2.9 Billion Sale Of Soleno Therapeutics To Neurocrine Biosciences - Mondaq
This Soleno Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Sahm
Soleno Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Anno - The National Law Review
Soleno Therapeutics Inc. (SLNO) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit – RGRD Law - marketscreener.com
INVESTOR ALERT: Soleno Therapeutics Inc. (SLNO) Investors - GlobeNewswire
SLNO Stockholders Have Opportunity to Lead Soleno Therapeutics, I - The National Law Review
Soleno Therapeutics, Inc. (SLNO) Investors: May 5, 2026, Deadline in Securities Fraud Class Action Lawsuit - Morningstar
SLNO ALERT: Hagens Berman Alerts Soleno (SLNO) Investors to - GlobeNewswire
Soleno Therapeutics (NASDAQ:SLNO) Tracks Rating Downgrade Amid Nasdaq Index Activity - Kalkine Media
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Soleno Therapeutics Stock Rallies 56.4% in a Week: Here's Why - Yahoo Finance
SLNO Stockholders Have Opportunity to Lead Soleno Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
HC Wainwright & Co. downgrades Soleno Therapeutics (SLNO) - MSN
A Look At Soleno Therapeutics (SLNO) Valuation After Its Recent Share Price Surge - Sahm
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application - GlobeNewswire
Gemini Space Station, Inc. Notice of May 18, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
Enphase Energy, Inc. Notice of April 20, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNO - ChartMill
Neurocrine Grows in Endocrinology, Rare Disease with $2.9B Soleno Buyout - Genetic Engineering and Biotechnology News
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Commercial Viability Risks: Levi & Korsinsky - Business Wire
Neurocrine’s $2.9B Soleno Buyout Brings What Could Become Its Next Blockbuster Drug - Dealbreaker
SLNO SHAREHOLDER UPDATE: Soleno (SLNO) Facing Securities Class Action After DCCR Launch Setback, Share Drop-- Hagens Berman - PR Newswire
Deadline Alert: Soleno Therapeutics, Inc. (SLNO) - GlobeNewswire
SOLENO THERAPEUTICS, INC. (SLNO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Soleno Therapeutics, Inc. Investors of Upcoming Deadline - TMX Newsfile
Analysts Offer Insights on Healthcare Companies: Soleno Therapeutics (SLNO) and Viridian Therapeutics (VRDN) - The Globe and Mail
Baird Downgrades Soleno Therapeutics to Neutral From Outperform, Cuts Price Target to $53 From $107 - Moomoo
Neurocrine Soleno Deal Adds Vykat XR And Alters Valuation Story - Yahoo Finance
Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit - FinancialContent
Company News for Apr 7, 2026 - Yahoo Finance
SLNO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Soleno Therapeutics, Inc. Securities Lawsuit -- The Gross Law Firm - ChartMill
Soleno Therapeutics Pulls Europe Drug Filing After $2.9 Billion Neurocrine Deal - TechStock²
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Oppenheimer Downgrades Soleno Therapeutics to Market Perform From Outperform - Moomoo
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion | Vykat XRNews and Statistics - IndexBox
Neurocrine Biosciences Weighs Soleno Deal To Broaden CNS Portfolio - simplywall.st
Soleno Therapeutics withdraws European application for PWS treatment By Investing.com - Investing.com South Africa
Soleno Withdraws EU Application for Prader-Willi Treatment - TipRanks
TD Cowen Downgrades Soleno Therapeutics to Hold From Buy, Adjusts PT to $53 From $85 - marketscreener.com
Soleno Therapeutics withdraws European application for PWS treatment - Investing.com
Soleno Therapeutics Incwithdraws marketing authorization application for Viokat in EuropeSEC filing - marketscreener.com
Soleno Therapeutics withdraws EU marketing application for VIOKAT (VYKAT XR) - TradingView — Track All Markets
0.62%
자본화:
|
볼륨(24시간):